Rallybio Corp
RLYB · XNASCIK 1739410fmd_0XYZJE9A46M33A193K769928KRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 26 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 1 | 1 |
| Research and development | 18 | 27 | 41 | 54 | 42 | 20 |
| Total operating expenses | 25 | 46 | 68 | 79 | 61 | 34 |
| Operating income | (25) | (46) | (68) | (79) | (60) | (33) |
| Interest expense | 0 | 0 | 0 | – | – | – |
| Interest and investment income | 0 | 0 | 2 | 6 | 4 | 2 |
| Other non-operating income (expense) | 0 | 0 | 2 | 6 | 5 | 25 |
| Income before taxes | (25) | (46) | (66) | (73) | (56) | (9) |
| Income tax expense | (0) | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (25) | (46) | (66) | (73) | (56) | (9) |
| Net income | (26) | (47) | (67) | (75) | (58) | (9) |